 |
         
|
COMMENTS: Nose not Needle
This week's guidelines for the influenza vaccine could be a bonanza for Medimmune, the pharmaceutical firm that makes 'Flu Mist. NBC's Robert Bazell explained. In most years, the 'flu vaccine benefits the elderly population whereas the 'Flu Mist inhaled form has been approved for use only by children, teenagers and young adults, "a commercial failure," as Bazell put it. The H1N1 strain of the swine 'flu turns those demographics on their head. This fall's vaccine is targeted at 'Flu Mist's sweet spot. "Companies making shots against swine 'flu have had big production problems but the 'Flu Mist production is going so well that the company has run out of the sprayers that deliver it."
READER COMMENTS BELOW:
You must be logged in to this website to leave a comment. Please click here to log in so you can participate in the discussion.
